Literature DB >> 3280609

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies.

C S Goodwin1, B J Marshall, E D Blincow, D H Wilson, S Blackbourn, M Phillips.   

Abstract

One hundred patients with duodenal ulceration and Campylobacter pylori in their stomach were entered into a double blind placebo controlled prospective study. Treatment schedules were cimetidine and placebo, or cimetidine and tinidazole, or colloidal bismuth subcitrate (CBS) and placebo, or CBS and tinidazole. Seventeen per cent of isolates of C pylori obtained at the first endoscopy were resistant to tinidazole and 70% of the second isolates from patients given cimetidine and tinidazole became tinidazole resistant. Suspensions of nitroimidazole sensitive cultures of C pylori showed that three of 22 isolates had a nitroimidazole resistant subpopulation. In patients who healed and remained free of C pylori after treatment ulcers recurred less often than in patients who healed but retained C pylori (23% v 73% over 12 months, p less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280609      PMCID: PMC1141380          DOI: 10.1136/jcp.41.2.207

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  9 in total

1.  Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate.

Authors:  C A McNulty; J C Gearty; B Crump; M Davis; I A Donovan; V Melikian; D M Lister; R Wise
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-13

2.  Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents.

Authors:  C A McNulty; J Dent; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 3.  Campylobacter pyloridis, gastritis, and peptic ulceration.

Authors:  C S Goodwin; J A Armstrong; B J Marshall
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

4.  Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.

Authors:  B J Marshall; J A Armstrong; G J Francis; N T Nokes; S H Wee
Journal:  Digestion       Date:  1987       Impact factor: 3.216

5.  Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma.

Authors:  R P Beaney; A A Lammertsma; T Jones; C G McKenzie; K E Halnan
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

6.  Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa.

Authors:  C S Goodwin; E D Blincow; J R Warren; T E Waters; C R Sanderson; L Easton
Journal:  J Clin Pathol       Date:  1985-10       Impact factor: 3.411

7.  Intracellular penetration and antimicrobial activity of antibiotics.

Authors:  R F Jacobs; C B Wilson
Journal:  J Antimicrob Chemother       Date:  1983-10       Impact factor: 5.790

8.  The minimum inhibitory and bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis.

Authors:  C S Goodwin; P Blake; E Blincow
Journal:  J Antimicrob Chemother       Date:  1986-03       Impact factor: 5.790

9.  Does treatment with cimetidine extended beyond initial healing of duodenal ulcer reduce the subsequent relapse rate?

Authors:  K D Bardhan; D S Cole; B W Hawkins; C R Franks
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-27
  9 in total
  59 in total

1.  Direct and indirect methods of measuring Helicobacter pylori drug susceptibility in vitro.

Authors:  A McLaren
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

Review 2.  Helicobacter pylori and duodenal ulcer. Evidence suggesting causation.

Authors:  F Mégraud; H Lamouliatte
Journal:  Dig Dis Sci       Date:  1992-05       Impact factor: 3.199

Review 3.  Bacterial challenges and evolving antibacterial drug strategy.

Authors:  B Watt; J G Collee
Journal:  Postgrad Med J       Date:  1992-01       Impact factor: 2.401

4.  Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.

Authors:  Ping-I Hsu; Feng-Woei Tsai; Sung-Shuo Kao; Wen-Hung Hsu; Jin-Shiung Cheng; Nan-Jing Peng; Kuo-Wang Tsai; Huang-Ming Hu; Yao-Kuang Wang; Seng-Kee Chuah; Angela Chen; Deng-Chyang Wu
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

5.  Susceptibility of Helicobacter pylori to metronidazole.

Authors:  M López-Brea; E Martín; C López-Lavid; J C Sanz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

6.  In vitro selection of resistant Helicobacter pylori.

Authors:  C E Haas; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Bactericidal activity of antimicrobial agents against slowly growing Helicobacter pylori.

Authors:  M R Millar; J Pike
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

8.  Role of metronidazole resistance in therapy of Helicobacter pylori infections.

Authors:  H Rautelin; K Seppälä; O V Renkonen; U Vainio; T U Kosunen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

9.  Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.

Authors:  F Mégraud; A Occhialini; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.

Authors:  Sebahat Basyigit; Ayse Kefeli; Ferdane Sapmaz; Abdullah Ozgür Yeniova; Zeliha Asilturk; Murat Hokkaomeroglu; Metin Uzman; Yasar Nazligul
Journal:  Bosn J Basic Med Sci       Date:  2015-10-25       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.